Systemic lupus erythematosus is associated with increased incidence of hematologic malignancies: A meta-analysis of prospective cohort studies
Systemic lupus erythematosus is associated with increased incidence of hematologic malignancies: A meta-analysis of prospective cohort studies
复制标题
DOI：
10.1016/j.leukres.2014.06.025
复制
发表时间：
2014-09-01
影响因子：
2.7
通讯作者：
Castillo, Jorge J.
中科院分区：
文献类型：
--
作者：
Apora, Emmanuel;O'Brien, Jennifer;Castillo, Jorge J.
我们的目的是通过前瞻性队列研究的荟萃分析，确定SLE成人患者发生淋巴瘤、白血病和骨髓瘤的风险。从1995年到2013年的文献检索显示了8项评估这种关联的研究。感兴趣的结果是标准化发生率（SIR）。我们的研究纳入了约68，000例SLE患者队列中的401例病例，并显示与一般人群相比，SLE患者中所有血液系统恶性肿瘤（SIR 2.9）、非霍奇金淋巴瘤（SIR 5.7）、霍奇金淋巴瘤（SIR 3.1）、白血病（SIR 2.3）和骨髓瘤（SIR 1.5）的发病率增加。无论年龄、性别或地理区域如何，SIR增加是一致的。(C)2014爱思唯尔有限公司版权所有。
Our objective was to define the risk of lymphoma, leukemia and myeloma in adult patients with SLE with a meta-analysis of prospective cohort studies. A literature search from 1995 to 2013 revealed eight studies evaluating this association. The outcome of interest was the standardized incidence ratio (SIR). Our study included 401 cases in a cohort of approximately 68,000 SLE patients, and showed an increased incidence of all hematologic malignancies (SIR 2.9), non-Hodgkin lymphoma (SIR 5.7), Hodgkin lymphoma (SIR 3.1), leukemia (SIR 2.3) and myeloma (SIR 1.5) in SLE patients compared with the general population. The increased SIR was consistent regardless of age, sex or geographical region. (C) 2014 Elsevier Ltd. All rights reserved.